CNBC has a very interesting series of articles and videos on what they call the CNBC Disruptor 50, a list of 50 “disruptors” in several industries, including Healthcare, Travel, Transport, Retail, IT, Financial Services and others. Any disruptors creeping up on your portfolio companies yet?
Interesting, short interview with Athenahealth CEO Jonathan Bush. A reminder of the sometimes almost insurmountable barriers of inefficient habits and practices in some sectors. The potential for IT-based revolutions in healthcare is huge, however the questions of “when” and “how” are still hard to answer. Yet keeping track of the “cost control/ accountability” trend in HC is vital.
DLD 2012 has started today in Munich and runs until Jan. 24th. In it, people as diverse as Sheryl Sandberg, Arianna Huffington, the Dyson family and Hiroshi Mikitani share their views on what matters to them. The themes are varied and the program is packed with interesting talks and panels. In the age of multi-disciplinary events, this is one of the best.
We highlight three articles about old truths and new business models. First the truth about economic models, according to the Scientific American magazine; second an old and huge sector disrupted by tiny start-ups; and third an entirely new business model that is becoming very relevant.
When we mention good capital allocators, one imagines managers that deploy capital well – who invest shrewdly in existing and new businesses, and when the returns on those investments seem poor, return capital in the best possible way. Thermo Fisher’s management has been a case study in excellence in all these regards. What isn’t intuitive is that capital allocation involves divestitures as well – and the latest from Thermo suggests that they also do a great job when it comes to selling assets.
A NYT article highlights research being done on aging at MIT and in other places, in which the idea behind the effort is no longer just for medical or policy-making, macro-economic, demographic-challenge stuff: it’s about senior citizens as a consumer force to be reckoned with, and how to market for them. As one person says in the article: “If you are a Fortune 100 company, or an inventor in a garage, where are you going to find another demographic that is that large, that robust in spending power, that open to new possibilities, and that underserved?”
Brazilian newspaper Valor Econômico featured an article today on one of our global favorites: Thermo Fisher. It’s an opportunity to continue learning about a company that we’ve dealt with since 2006, and it’s always great when a global analysis effort pays unexpected dividends.
Now that the U.S. Healthcare bill has passed and just been signed into law, it’s interesting to notice the amount of noise generated in the past two days. Newspaper and sell-side reports are booming with articles and so-called analysis of what this means to investors, but right now it’s probably better to “do something by doing nothing”.
Stanford U. is starting a program to advocate against the influence of drug and medical device cies. on physicians, a practice that spins some US$1 billion per year. The problem is that the program is being partly funded by Pfizer. Stanford claims that Pfizer’s support was 100% voluntary and that there are no strings attached. How far can we push the boundaries on conflicts of interest? And if it appears conflicted, doesn’t it defeat the purpose from the get-go?
Motivated by the recent LBO of IMS Health by TPG (the private equity group) and Canada Pension Plan, we have a few links inside about the company. We had been looking at it at least since 2007, when we started to look at the healthcare industry globally.